Development and Validation of RP-Chiral HPLC Method for Determination of (R)-Enantiomer Excess Content in Efavirenz

simple, specific, linear, accurate and precise reverse phase chiral HPLC method was developed for the separation of efavirenz enantiomers by using the Lux Amylose-2 column containing amylose tris(5-chloro-2-methyl phenyl carbamate) as a stationary phase. The mobile phase consists of 0.1 % formic acid in water and acetonitrile (55:45, v/v). The flow rate was kept at 1.0 mL/min and the detection wavelength used 252 nm and the column temperature was set at 25 ºC. The limit of detection was 0.01 mg/mL and the limit of quantification was 0.04 mg/mL. The linearity calibration curve of (R)-enantiomer was shown well from the range of 0.04 mg/mL to 0.4 mg/mL. The values of the correlation coefficient were 0.999 and 0.999 for (R)-enantiomer and (S)-efavirenz, respectively. The percentage recoveries of (R)-enantiomer from efavirenz drug substance were ranged from 93.5% to 107.5%. The results demonstrated that developed RP-chiral HPLC method was simple, precise, robust and applicable for the estimation of (R)-enantiomer in efavirenz API. This method was validated in as per ICH Q2 (R1) and USP validation of compendial methods <1225>.

[1]  N. Mazumder,et al.  Enantiomeric Recognition and Separation by Chiral Nanoparticles , 2019, Molecules.

[2]  G. Meintjes Efavirenz , 2018, Reactions Weekly.

[3]  A. Nag Asymmetric Synthesis of Drugs and Natural Products , 2018 .

[4]  O. Coskun Separation techniques: Chromatography , 2016, Northern clinics of Istanbul.

[5]  R. Silvestri,et al.  Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors , 2016, Molecules.

[6]  N. Boechat,et al.  Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. , 2016, European journal of medicinal chemistry.

[7]  I. Truter,et al.  Efavirenz : a review of the epidemiology, severity and management of neuropsychiatric side-effects , 2015 .

[8]  F. Maggiolo Efavirenz: a decade of clinical experience in the treatment of HIV , 2009, The Journal of antimicrobial chemotherapy.

[9]  Silas W Smith Chiral toxicology: it's the same thing...only different. , 2009, Toxicological Sciences.

[10]  B. Best,et al.  Efavirenz – Still First-line King? , 2008, Expert opinion on drug metabolism & toxicology.

[11]  F. Wit,et al.  Efavirenz: a review , 2007, Expert opinion on pharmacotherapy.

[12]  Sarah K Branch,et al.  Guidelines from the International Conference on Harmonisation (ICH). , 2005, Journal of pharmaceutical and biomedical analysis.

[13]  D. Thiébaut,et al.  Evaluation of a ristocetin bonded stationary phase for subcritical fluid chromatography of enantiomers. , 2003, Chirality.

[14]  R. C. Williams,et al.  Column selection and method development for the determination of the enantiomeric purity of investigational non-nucleoside reverse transcriptase inhibitors. , 2001, Chirality.

[15]  K. Groen,et al.  Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. , 1994, Chirality.